glp 1 agonist fda approval just approved orforglipron (Foundayo), Eli Lilly's oral GLP-1 receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest FDA approves first generic GLP-1
Pay in 4 interest-free payments of $7.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5







/prd-cl/product-medias/8f447f01-b0ce-420c-9118-a623209db925/MK1Y4BURKV/MK1Y4BURKV-1/1753891351251-MK1Y4BURKV-1-3.png)












